Citigroup Inc Neuro Pace Inc Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Neuro Pace Inc stock. As of the latest transaction made, Citigroup Inc holds 1,034 shares of NPCE stock, worth $13,276. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,034

Previous 8,594 87.97%

Holding current value

$13,276

Previous $95,000 89.47%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$8.25 - $10.6 $62,370 - $80,136	-7,560 Reduced 87.97%	1,034 $10,000
Q2 2025 Aug 11, 2025	SELL	$10.34 - $18.13 $15,510 - $27,195	-1,500 Reduced 14.86%	8,594 $95,000
Q1 2025 May 12, 2025	SELL	$10.04 - $14.94 $10,170 - $15,134	-1,013 Reduced 9.12%	10,094 $124,000
Q4 2024 Feb 12, 2025	BUY	$5.9 - $11.93 $7,451 - $15,067	1,263 Added 12.83%	11,107 $124,000
Q3 2024 Nov 12, 2024	BUY	$6.65 - $8.46 $45,718 - $58,162	6,875 Added 231.56%	9,844 $68,000
Q2 2024 Aug 12, 2024	SELL	$6.38 - $15.33 $463,947 - $1.11 Million	-72,719 Reduced 96.08%	2,969 $22,000
Q1 2024 May 10, 2024	BUY	$9.78 - $17.5 $397,723 - $711,672	40,667 Added 116.12%	75,688 $999,000
Q4 2023 Feb 09, 2024	BUY	$5.9 - $10.31 $189,018 - $330,301	32,037 Added 1073.63%	35,021 $361,000
Q3 2023 Nov 09, 2023	BUY	$4.0 - $9.73 $11,936 - $29,034	2,984 New	2,984 $29,000
Q2 2022 Aug 10, 2022	SELL	$4.95 - $8.7 $960 - $1,687	-194 Reduced 75.78%	62 $0
Q1 2022 May 12, 2022	SELL	$7.06 - $11.57 $11,175 - $18,315	-1,583 Reduced 86.08%	256 $2,000
Q4 2021 Feb 10, 2022	BUY	$8.63 - $17.36 $8,811 - $17,724	1,021 Added 124.82%	1,839 $19,000
Q3 2021 Nov 10, 2021	BUY	$15.85 - $25.07 $12,965 - $20,507	818 New	818 $13,000

Others Institutions Holding NPCE

# of Institutions

Shares Held

24.3M

Call Options Held

30.6K

Put Options Held

38.6K

View Full List

About NeuroPace Inc

Ticker NPCE
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,846,900
Market Cap $319M
Description
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...

More about NPCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account